無料プレビュー

Esperion Therapeutics, Inc. (ESPR) · NASDAQ Global Market

プロフィール

Esperion Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease and elevated LDL-cholesterol. Its lead products NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) are indicated for patients unable or unwilling to take statins, with expanded indications for cardiovascular risk reduction approved in 2024. The company operates through direct U.S. sales and collaboration agreements with international partners in Europe, Japan, South Korea, Taiwan, and other terri

主要指標

株価: $3.18 (0.00%)
時価総額: 7億ドル
PER（今期予想）: -79.5
PBR: -2.6
配当利回り: —
52週レンジ: $1.13 – $4.17
業種: Healthcare / Biotechnology
上場: NASDAQ Global Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-08-04 · 更新: 2026-10-09